Every 8-K that Aveanna Healthcare Holdings Inc. (AVAH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AVAH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVAH filings page.
Aveanna Healthcare Holdings, Inc. (AVAH) said Steven E. Rodgers, a Class II director, notified the company on October 1, 2026, of his decision to resign, effective immediately. Before resigning, Rodgers was an independent director and served on both the Audit Committee and the Compensation Committee. The company said his decision was not due to any disagreement concerning its operations, policies, or practices.
Aveanna Healthcare Holdings, Inc. (AVAH) reports that certain existing stockholders completed a secondary public offering of its common stock. On August 20, 2026, the company and the selling stockholders entered into an Underwriting Agreement with RBC Capital Markets, LLC for the sale by those stockholders of 15,000,000 shares of Aveanna common stock at a public offering price of $11.75 per share. The selling stockholders also granted the underwriter a 30‑day option to purchase up to an additional 2,250,000 shares. The secondary offering closed on August 24, 2026. Aveanna did not issue any new shares and did not receive any proceeds from this offering; all proceeds went to the selling stockholders.
Aveanna Healthcare Holdings Inc. outlines its homecare platform, 2026 outlook and recent performance across three segments: Private Duty Services, Home Health & Hospice, and Medical Solutions. For full year 2026, management targets revenue >$2.68 billion, gross margin of 32.2% and Adjusted EBITDA >$365 million, supported by a national footprint of 403 locations in 39 states, more than 30,000 caregivers and 48.9 million annualized homecare hours.
For Q2 2026, revenue was $670.5 million, up 13.7% from Q2 2025, with gross margin of $218.5 million and Adjusted EBITDA of $95.4 million. Segment revenue growth was led by Private Duty Services at 14.0%, Home Health & Hospice at 14.8% and Medical Solutions at 9.4%, each driven primarily by higher volumes. Free cash flow for 2026 is shown as positive $75.4 million, an improvement of $38.5 million versus 2025.
Liquidity totals $432.7 million, including $97.2 million of cash, with $1,483 million of variable-rate debt partially hedged by interest rate caps. Management highlights long-term organic growth and tuck-in M&A, a large homecare market of about $183 billion TAM growing ~6.5%, and increasing use of value-based and preferred payor agreements.
Aveanna Healthcare Holdings Inc. reported strong growth for the three and six-month periods ended July 4, 2026. For the quarter, revenue was $670.5 million, up 13.7% from $589.6 million a year earlier, driven by increases across its PDS, HHH, and MS segments. Quarterly net income rose to $40.3 million (diluted EPS $0.18) from $27.0 million (EPS $0.13), while Adjusted EBITDA was $95.4 million, up 8.0%, although the Adjusted EBITDA margin declined to 14.2% from 15.0% as gross margin percentage compressed.
For the first six months, revenue reached $1,318.4 million, an increase of 14.8%, with net income of $81.9 million versus $32.2 million and Adjusted EBITDA of $179.8 million, up 15.4%. Aveanna raised its full-year 2026 outlook, guiding to revenue of more than $2.68 billion and Adjusted EBITDA of more than $365 million. As of July 4, 2026, the company held $97.2 million of cash and $1,483.4 million of total indebtedness, with additional borrowing capacity under its securitization facility and revolving credit facility.
Aveanna Healthcare Holdings Inc. announced that on August 5, 2026, Dr. Erica Schwartz, a Class III, independent director, resigned from its Board of Directors, effective immediately. Her departure is tied to her nomination and subsequent confirmation as Director of the United States Centers of Disease Control and Prevention.
The company states that Dr. Schwartz’s resignation was not due to any disagreement regarding its operations, policies, or practices. Before stepping down, she served as Chair of the Clinical Quality Committee, providing board-level oversight of clinical quality matters.
Aveanna Healthcare Holdings Inc. has completed its acquisition of Family First Homecare, a multi-state pediatric home care provider with 27 locations across seven states. The company paid a cash purchase price of $175.5 million, funded entirely with cash on hand, to acquire all membership interests of Family First Holding, LLC.
Following this deal, Aveanna updated its full fiscal year 2026 outlook to reflect Family First’s contribution. Revenue guidance increased to $2.63–$2.65 billion, up from $2.56–$2.58 billion, driven by Family First’s revenue guidance of $70.0 million. Adjusted EBITDA guidance rose to $338–$342 million, from $328–$332 million, reflecting Family First’s Adjusted EBITDA guidance of $10.0 million.
Aveanna Healthcare Holdings Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 29, 2026. Stockholders elected three Class II directors—Rodney D. Windley, Sam Weil, and Steven E. Rodgers—to three-year terms ending at the 2029 Annual Meeting.
Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending January 2, 2027, with 198,808,170 votes for and 477,379 against. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 160,094,458 votes for and 19,490,871 against. No other matters were considered.
Aveanna Healthcare Holdings Inc. announced that its subsidiary Aveanna Healthcare LLC has repriced its first lien credit and revolving credit facilities. The amendment refinances outstanding senior secured term loans with new 2026 Term Loans totaling $1,318,375,000 and renews a $250,000,000 senior secured revolving credit facility.
The 2026 Facilities reduce applicable interest rate margins by 0.50 percentage points. Both the term loans and revolver now bear interest at, at the borrower’s election, Term SOFR plus a 3.25% margin or a base rate plus a 2.25% margin. Margins may be reduced by an additional 0.25 percentage points if the borrower obtains a rating of at least B2 or B from specified credit rating agencies, while other key credit agreement terms remain largely unchanged.
Aveanna Healthcare Holdings Inc. furnished an investor presentation outlining 2026 guidance and strong early-year performance. The company targets $2.56–$2.58 billion in 2026 revenue and $328–$332 million in Adjusted EBITDA, supported by a national platform of 379 locations across 39 states and 29,000 caregivers.
For Q1 2026, revenue reached $647.9 million, up 15.9% year over year, while Adjusted EBITDA rose to $84.4 million, a 25.2% increase. Net income improved to $41.7 million, and operating cash flow turned positive at $4.3 million, a $12.9 million improvement versus Q1 2025.
The presentation highlights segment growth in Private Duty Services, Home Health & Hospice, and Medical Solutions, along with a focus on value-based agreements and preferred payor relationships. Aveanna reports liquidity of $524.8 million against total variable-rate debt of $1,483 million, with interest rate swaps and caps in place, and free cash flow of $(3.8) million for Q1 2026.
Aveanna Healthcare Holdings reported strong results for the three-month period ended April 4, 2026, with revenue of $647.9 million, up 15.9% from $559.2 million a year earlier. Net income rose to $41.7 million from $5.2 million, and diluted EPS increased to $0.19 from $0.03.
Adjusted EBITDA was $84.4 million, a 25.2% increase, and operating income margin improved to 10.7% of revenue. Management raised full-year 2026 guidance, now expecting revenue between $2.56 and $2.58 billion and Adjusted EBITDA between $328 and $332 million, reflecting confidence in ongoing growth across its home care segments.
Aveanna Healthcare Holdings Inc. furnished a March 2026 investor presentation outlining recent performance, capital structure and long‑term growth plans. For Q4 2025, revenue rose from $519.9m to $662.5m, a 27.4% increase, while gross margin grew from $171.7m to $213.3m. Adjusted EBITDA increased from $55.2m to $85.0m, up 54.0%. For full‑year 2025, operating cash flow was $125.9m and free cash flow was $131.0m. The company guided 2026 revenue to $2.54b–$2.56b with Adjusted EBITDA of $318m–$322m, supported by a national platform of 366 locations in 38 states and 29,000 caregivers. Liquidity totaled $528.8m, against $1,487m of variable‑rate debt, partially hedged with swaps and caps. Aveanna highlights value‑based growth across Private Duty Services, Home Health & Hospice, and Medical Solutions, each with targeted organic growth and margin ranges.
Aveanna Healthcare reported strong growth for the quarter and fiscal year ended January 3, 2026. Fourth quarter revenue was $662.5 million, up 27.4% from the prior year, with net income of $178.8 million versus $29.2 million. Adjusted EBITDA rose to $85.0 million, a 54.0% increase.
For 2025, revenue reached $2,433.2 million, up 20.2%, and the company swung to full-year net income of $225.0 million from a $10.9 million loss. Full-year Adjusted EBITDA grew to $320.9 million, up 74.8%. Management reaffirmed 2026 guidance for revenue of $2.54–$2.56 billion and Adjusted EBITDA of $318–$322 million.
Aveanna also agreed to acquire Family First Homecare for $175.5 million, expected to close in the second fiscal quarter of 2026, expanding its pediatric home care footprint. As of January 3, 2026, the company had cash of $193.3 million, free cash flow of $131.0 million for 2025, and total indebtedness of $1,486.7 million.
Aveanna Healthcare Holdings Inc. is expanding its pediatric home care network by agreeing to acquire Family First Holding, LLC for a cash purchase price of $175.5 million, subject to customary adjustments. Aveanna plans to fund the deal with cash on hand and existing short-term credit facility borrowings.
Family First Homecare is a multi-state pediatric home care provider with 27 locations across seven states, focused on skilled Private Duty Nursing. The transaction is expected to close in Aveanna’s second fiscal quarter of 2026, subject to Hart-Scott-Rodino clearance, customary closing conditions, and the absence of a material adverse effect.
Aveanna Healthcare Holdings Inc. reported that Robert M. Williams, Jr. has resigned from its Board of Directors effective February 27, 2026. He had served as a Class I director and was a member of the Nominating and Corporate Governance, Compensation, and Clinical Quality and Compliance Committees.
The company stated that Mr. Williams’ decision to resign was not due to any disagreement with Aveanna regarding its operations, policies, or practices. The filing is signed by Chief Executive Officer Jeff Shaner.
Aveanna Healthcare Holdings Inc. updated employment agreements for its President and CEO Jeff Shaner, CFO Matthew Buckhalter, and Chief Legal Officer Jerry Perchik through its Aveanna Healthcare, LLC subsidiary. The new contracts set minimum annual base salaries of $750,000 for Shaner, $500,000 for Buckhalter, and $450,000 for Perchik, with target annual bonuses equal to 100%, 75%, and 75% of salary, respectively, plus eligibility for discretionary equity awards under the 2021 Stock Incentive Plan.
If terminated without cause or resigning for good reason outside a change in control, Shaner is eligible for cash severance equal to 2x salary plus target bonus, while Buckhalter and Perchik receive 1x, along with pro‑rated bonuses, partial vesting of equity, and subsidized COBRA for up to 24 months for Shaner and 12 months for the others. During a defined change in control period, severance rises to 2.5x salary plus target bonus for Shaner and 2x for the others, full vesting of equity based on actual or target performance, and COBRA-related cash or subsidies for 30 months for Shaner and 24 months for the others. All severance requires a signed release and continued compliance with non‑competition, non‑solicitation, non‑disparagement, and confidentiality covenants.
Aveanna Healthcare Holdings Inc. filed a current report describing new financial outlook information. On January 14, 2026, the company issued a press release updating its full year guidance for fiscal 2025 and announcing its full year guidance for fiscal 2026. The guidance details are contained in a press release furnished as Exhibit 99.1 and a January 2026 investor presentation furnished as Exhibit 99.2. These materials are provided for informational purposes under Items 2.02 and 7.01 and are treated as “furnished,” not “filed,” under securities laws.
Aveanna Healthcare Holdings (AVAH) filed an 8-K announcing a Second Amendment to its Amended and Restated Stockholders Agreement and a Board change. The amendment limits executive stock transfers: any sale or transfer of common shares by covered executives requires prior approval by the Compensation Committee and must keep each executive in compliance with the Company’s Stock Ownership Guidelines. “Sell to cover” transactions for exercise price or tax withholding are exempt. The amendment also permits certain Other Stockholders to transfer shares without restriction or consent.
Separately, Christopher Gordon resigned as a Class II director, stating no disagreement with the Company. The Board appointed Sam Weil (age 35), a Bain Capital Principal, as a Class II director and member of the Compensation Committee, serving until the 2026 Annual Meeting. The Board determined he is independent under SEC and Nasdaq rules, and as a Bain affiliate he will not receive director compensation.
Aveanna Healthcare Holdings Inc. (AVAH) furnished an investor presentation under Regulation FD. On November 7, 2025, the company made a financial presentation available to investors, attached as Exhibit 99.1 to an 8‑K.
The materials are also posted in the Investors section of aveanna.com. The company states it uses its website to distribute important and time‑critical information. The information in Item 7.01, including Exhibit 99.1, is furnished and not filed, and is not subject to Section 18 liabilities or incorporated by reference unless specifically stated.
Aveanna Healthcare Holdings Inc. (AVAH) furnished an 8-K announcing it issued a press release with financial results for the three and nine-month periods ended September 27, 2025. The press release is provided as Exhibit 99.1 and relates to Item 2.02 (Results of Operations and Financial Condition), with related information also referenced under Item 7.01 (Regulation FD).
The company states the information in this report, including Exhibit 99.1, is “furnished” and not “filed,” which means it is not subject to Section 18 liabilities and will only be incorporated by reference in other filings if specifically stated. The filing is signed by the Chief Accounting Officer as of November 6, 2025.
Aveanna Healthcare Holdings Inc. (AVAH) reported that selling stockholders affiliated with J.H. Whitney Equity Partners VII completed a secondary offering of 10,000,000 shares of common stock at $9.00 per share. The underwriters were led by Jefferies and J.P. Morgan, and the transaction closed on October 23, 2025.
The selling stockholders also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares. Aveanna did not issue any shares in this sale and did not receive proceeds, as all shares were sold by existing holders.
Aveanna Healthcare Holdings Inc. furnished an 8-K to announce it issued a press release with preliminary results for the three-month period ended September 27, 2025. The press release, dated October 21, 2025, is included as Exhibit 99.1.
The company states the information under Item 2.02 is “furnished” and not “filed” under the Exchange Act, and will only be incorporated by reference into other filings if specifically stated.
Aveanna Healthcare Holdings Inc. furnished an investor presentation as part of a current report. On September 29, 2025, the company made a financial presentation available to investors and attached it as Exhibit 99.1 to this report. The presentation is also accessible through the Investors section of Aveanna’s website.
The company explains that it routinely uses its website and investor presentations to share important and time-sensitive information. The materials in this report, including Exhibit 99.1, are designated as “furnished” rather than “filed,” which means they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other SEC filings unless specifically referenced.
Aveanna Healthcare Holdings Inc. amended its first-lien credit agreement through a refinancing and incremental debt transaction. The company’s subsidiary put in place new first-lien term loans totaling $1.325 billion and expanded its revolving credit commitments to $250 million, replacing the prior term and revolving facilities. The new revolving facility matures on September 17, 2030, and the new term loans mature on September 17, 2032, with 1% annual amortization and original issue discount of 99.75% of par.
The term loans and revolver bear interest at the borrower’s option at Term SOFR plus a margin of 3.75% or a base rate plus 2.75%, with potential margin step-downs based on first-lien net leverage. Aveanna used proceeds from the new term loans to fully refinance its existing first-lien term loans and repay its $415 million second-lien term loan, as well as to pay accrued interest and fund working capital and general corporate purposes.
On 8 Aug 2025 Aveanna Healthcare Holdings Inc. (AVAH) filed a Form 8-K under Item 7.01 (Regulation FD) to furnish an updated investor presentation (Exhibit 99.1). The deck is available in the “Investors” section of the company’s website and via IR e-mail alerts. Because the material is classified as “furnished,” it is not subject to Section 18 liability and will only be incorporated into other SEC filings if specifically referenced. Aveanna reiterates that its website is a primary channel for time-critical disclosures.
- No financial statements, earnings metrics or major transactions accompany this report.
- The 8-K is informational only and has no immediate accounting or voting impact.
Aveanna Healthcare (NASDAQ: AVAH) filed an 8-K announcing a Seventh Amendment to its receivables securitization facility. The amendment raises the maximum availability to $275 million, subject to the existing borrowing-base, and extends the scheduled termination date to three years from 25 June 2025. The change strengthens near-term liquidity and pushes out maturities without adding new restrictive covenants. The full text of the amendment is filed as Exhibit 10.1.